Price Alert

Insulet Corporation (PODD)

NASDAQ: PODD · Real-Time Price · USD

315.78

7.10 (2.30%)

At close: Aug 14, 2025, 3:59 PM

316.23

0.14%

After-hours: Aug 14, 2025, 07:53 PM EDT

2.30% (1D)

Bid	302.71
Market Cap	22.23B
Revenue (ttm)	2.36B
Net Income (ttm)	273.3M
EPS (ttm)	3.28
PE Ratio (ttm)	96.27
Forward PE	56.31
Analyst	Buy

Ask	321
Volume	654,657
Avg. Volume (20D)	881,308.5
Open	309.15
Previous Close	308.68
Day's Range	307.51 - 316.16
52-Week Range	180.31 - 329.33
Beta	1.35

About PODD

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol PODD

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for PODD stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Earnings Surprise

Insulet has released their quartely earnings on Aug 7, 2025:

Revenue of $649.1M exceeds estimates by $35.55M, with 32.88% YoY growth.

EPS of 1.17 exceeds estimates by 0.24, with 112.73% YoY growth.

Next Earnings Release

Insulet Corporation is scheduled to release its earnings on Nov 6, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

+9.47%

Insulet shares are trading higher after the compan... Unlock content with Pro Subscription

1 month ago

-4.52%

Shares of glucose monitor and insulin pump stocks are trading lower after the CMS proposed that continuous glucose monitors and insulin infusion pumps be reclassified under the frequent and substantial servicing payment category.

News

1 day ago · seekingalpha.com

Insulet's Q2 Beat Is Impressive, But The Elevated Valuation Makes The Stock A Hold

PODD delivered strong Q2 results, exceeding revenue guidance, improving gross margin, and launching the Omnipod 5 iPhone app, strengthening its ecosystem position. Omnipod 5's pharmacy channel penetra...

2 days ago · zacks.com

Insulet Q2 Earnings & Revenues Beat Estimates, Stock Up, Margins Rise

PODD posts strong Q2 earnings and revenues and lifts its 2025 outlook, marking a decade of 20%+ constant-currency growth.

3 days ago · zacks.com

Why Insulet (PODD) is a Top Growth Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

1 week ago · benzinga.com

Insulet Lifts Annual Forecast On Increased Adoption For Insulin Pump Omnipod 5

Insulet Corporation PODD reported second-quarter adjusted earnings of $1.17 per share, beating the consensus of 92 cents.

1 week ago · seekingalpha.com

Insulet Corporation (PODD) Q2 2025 Earnings Call Transcript

Insulet Corporation (NASDAQ:PODD ) Q2 2025 Earnings Call August 7, 2025 8:00 AM ET Company Participants Ana Maria Chadwick - Executive VP & CFO Ashley A. McEvoy - CEO, President & Director Eric Benjam...

1 week ago · zacks.com

Insulet (PODD) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Insulet (PODD) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to...

1 week ago · fool.com

Insulet (PODD) Q2 Revenue Jumps 33%

Insulet (PODD 9.87%), a medical device company specializing in wearable insulin delivery systems, released its second quarter 2025 earnings on August 7, 2025. The headline news was strong outperforman...

1 week ago · zacks.com

Insulet (PODD) Surpasses Q2 Earnings and Revenue Estimates

Insulet (PODD) came out with quarterly earnings of $1.17 per share, beating the Zacks Consensus Estimate of $0.93 per share. This compares to earnings of $0.55 per share a year ago.

1 week ago · investors.com

Insulet Pops As Diabetes Medtech Continues Its Streak Of 'Impressive Beat-And-Raises'

Insulet stock surged Thursday after the insulin pump-maker walloped second-quarter forecasts and raised its sales guidance for the year.

1 week ago · reuters.com

Insulet beats second-quarter profit estimates on strong demand for insulin pumps

Medical device maker Insulet beat Wall Street estimates for second-quarter profit and revenue on strong demand for its wearable insulin pumps, sending its shares up nearly 10% in premarket trading on ...

Load More News